血栓溶解增加了因缺血性中风引起的持续头痛的风险:一项前性观察性研究
Yi Zhang1, Wensheng Qu1,2, Cenk Ayata3,4
1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Brain and behavior
|March 7, 2024
概括
对于急性缺血性中风,静脉输血栓溶解 (IVT) 可能会增加患持续性中风后头痛的风险. 年龄较小,女性性别和后部循环中风也与持续的头痛有关.
科学领域:
- 神经学 神经学
- 脑卒中医学 脑卒中医学
- 头痛 疾病 头痛 疾病
背景情况:
- 归因于缺血性中风 (PHPIS) 的持续性头痛是一种已知的并发症.
- 内静脉血栓溶解 (IVT) 是一种标准的急性缺血性中风治疗方法.
- IVT对PHPIS发展的影响尚不清楚.
研究的目的:
- 确定缺血性中风后持续性头痛的发生率和临床特征.
- 为了比较接受IVT的患者与没有接受IVT的患者的PHPIS发病率.
- 为了确定患有持续性中风后头痛的风险因素.
主要方法:
- 在中国武汉的5个中风病房进行前性观察研究.
- 234名患者接受了IVT,226人没有.
- 使用结构化问卷进行6个月的随访.
主要成果:
- 所有患者中有12.0%的患者出现持续性头痛.
- 与非IVT组 (8.4%) 相比,IVT组中的PHPIS患病率明显高 (15.4%).
- 风险因素包括年轻的年龄,女性性别,后部循环心脏病发作和IVT的使用.
结论:
- IVT可能会影响持续性中风后头痛的发生.
- 在评估中风后持续头痛的患者时,临床医生应考虑IVT.
- 需要进一步的研究来阐明潜在的机制.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K


